Last reviewed · How we verify
Metformin / Pioglitazone Pill
This combination reduces blood glucose by decreasing hepatic glucose production (metformin) and improving insulin sensitivity in peripheral tissues (pioglitazone).
This combination reduces blood glucose by decreasing hepatic glucose production (metformin) and improving insulin sensitivity in peripheral tissues (pioglitazone). Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Metformin / Pioglitazone Pill |
|---|---|
| Sponsor | University of Catanzaro |
| Drug class | Antidiabetic combination (biguanide + thiazolidinedione) |
| Target | AMPK activation (metformin); PPAR-γ (pioglitazone) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Metformin is a biguanide that inhibits hepatic gluconeogenesis and increases glucose uptake in muscle and adipose tissue. Pioglitazone is a thiazolidinedione that activates peroxisome proliferator-activated receptor gamma (PPAR-γ), enhancing insulin sensitivity and glucose utilization in target tissues. Together, they provide complementary mechanisms for glycemic control in type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Gastrointestinal disturbance (nausea, diarrhea)
- Weight gain
- Fluid retention / edema
- Hypoglycemia
- Lactic acidosis (metformin)
- Heart failure exacerbation (pioglitazone)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metformin / Pioglitazone Pill CI brief — competitive landscape report
- Metformin / Pioglitazone Pill updates RSS · CI watch RSS
- University of Catanzaro portfolio CI